Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
Last trade$44.69
Day change+$0.145 (+0.33%)
Day range$43.29 – $45.13
Volume1,238,423
Market cap$5.43B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$5.43B
Price / earnings
—
Price / book
32.22×
Price / sales
9,533.47×
EV / sales
9,235.13×
EV / EBITDA
-12.92×
Profitability
Earnings per share
-$3.39
Return on assets
-92.74%
Return on equity
-245.21%
Dividend yield
0%
Liquidity and leverage
Debt / equity
1.16×
Current ratio
5.41×
Quick ratio
5.4×
Cash ratio
4.57×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$309.91M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for SRRK, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$570K
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$8K
$0
$0
$0
$0
$0
$0
$0
Gross profit
$562K
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$52.5M
$50.67M
$50.2M
$45.02M
$53.06M
$49.71M
$28.41M
$18.99M
Research and development
$54.13M
$58.23M
$51.81M
$46.88M
$50.49M
$62.4M
$48.68M
$50.37M
Total operating expenses
$106.62M
$108.9M
$102.02M
$91.9M
$103.55M
$112.11M
$77.09M
$69.36M
Operating income
-$106.06M
-$108.9M
-$102.02M
-$91.9M
-$103.55M
-$112.11M
-$77.09M
-$69.36M
Interest expense
-$4.63M
-$4.52M
-$2.3M
-$2.53M
-$1.33M
-$1.21M
-$1.82M
-$1.65M
Income before taxes
-$107.24M
-$109.9M
-$105.51M
-$90.97M
-$102.22M
-$110.03M
-$74.72M
-$66.45M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$107.24M
-$109.9M
-$105.51M
-$90.97M
-$102.22M
-$110.03M
-$74.72M
-$66.45M
Net income attributable to common shareholders
-$107.24M
-$109.9M
-$105.51M
-$90.97M
-$102.22M
-$110.03M
-$74.72M
-$66.45M
EBITDA
-$105.8M
-$108.6M
-$101.68M
-$91.47M
-$103.13M
-$111.69M
-$76.7M
-$68.96M
Basic earnings per share
-$0.81
-$0.84
-$0.83
-$0.75
-$0.90
-$0.98
-$0.67
-$0.61
Diluted earnings per share
-$0.81
-$0.84
-$0.83
-$0.75
-$0.90
-$0.98
-$0.67
-$0.61
Recent news
Company coverage with links to the original publishers.
The FDA has approved Isembyld (apitegromab-mstn), the first muscle-targeted therapy for spinal muscular atrophy (SMA) that works alongside existing SMN-targeted treatments. The approval is based on positive Phase 3 SAPPHIRE study results showing clinically meaningful improvements in motor function. This milestone represents a shift from slowing SMA progression to improving patient function and quality of life.
Scholar Rock's Chief Scientific Officer Mo Qatanani sold 14,898 shares on January 22, 2026, for approximately $695,938 as part of a pre-planned Rule 10b5-1 trading plan. The sale reduced his direct ownership to 85,660 shares (0.08% of outstanding shares). The company plans to launch its key product candidate apitegromab in U.S. and European markets in 2026, positioning it as a potential treatment for spinal muscular atrophy.
Commodore Capital fully exited its position in Scholar Rock, selling approximately 1.5 million shares in Q3, representing a $51 million transaction. The biotech company is preparing to resubmit its apitegromab biologics license application after a previous FDA rejection.
The FDA approved Novartis' Itvisma, a gene replacement therapy for spinal muscular atrophy (SMA), which can treat patients two years and older by addressing the genetic root cause of the disease with a one-time fixed dose.
Scholar Rock's stock dropped over 13% after the FDA designated a Catalent Indiana manufacturing facility as Official Action Indicated (OAI), following a previous FDA rejection of its spinal muscular atrophy drug application.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.